UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts
ASH Update on SCT for Myeloid and Lymphoid Leukemias: Apamistamab as Part of the Conditioning Regimen, Ruxolitinib for SR-aGVHD, Enasidenib as Post-Transplant Maintenance, Venetoclax Mono, Targeted T-Cell Maintenance
Login to view comments.
Click here to Login